Stock Taper 
| DATE | TYPE | RATIO |
|---|---|---|
| 2024-11-14 | Reverse | 1:20 |
| 2022-09-07 | Reverse | 1:25 |
| 2020-07-06 | Reverse | 1:33 |
InMed Pharmaceuticals Inc. is a Vancouver-based clinical-stage company developing cannabinoid-based therapies, including topical, ocular, and pain treatments, with products in various clinical and preclinical stages.
InMed's subsidiary BayMedica manufactures and sells high-purity, bioidentical rare cannabinoids as raw ingredients for the health and wellness industry, generating revenue while its pharmaceutical candidates are in clinical development.
In early June 2025, InMed Pharmaceuticals' stock price experienced a sudden and dramatic surge of approximately 200%. This significant increase was reportedly driven by heightened investor interest following speculation about a potential breakthrough in its cannabinoid-based therapeutics and rumors of upcoming partnerships.
InMed Pharmaceuticals entered into definitive agreements with an institutional investor for a private placement of 1,952,363 common shares at a price of $2.561 per share, raising approximately $5 million. This capital infusion is intended to fund the continued development of its pharmaceutical drug candidates, particularly its Alzheimer's program (INM-901), and support the commercial sales of its subsidiary, BayMedica LLC.
InMed Pharmaceuticals Inc. (NASDAQ: INM - Get Free Report) was the recipient of a significant decline in short interest in the month of September. As of September 15th, there was short interest totaling 15,876 shares, a decline of 48.4% from the August 31st total of 30,769 shares. Approximately 0.5% of the company's shares are short sold.
Overall rating: C
| PEER | PRICE | |
|---|---|---|
 ESLA | $0.44 | COMPARE |
 KZIA | $9.50 | COMPARE |
 BIVI | $1.47 | COMPARE |
 CNSP | $5.40 | COMPARE |
 GRI | $1.92 | COMPARE |
 JAGX | $4.69 | COMPARE |
 SILO | $1.42 | COMPARE |
 GNPX | $2.80 | COMPARE |
